for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bristol-Myers Squibb Co

BMY.N

Latest Trade

50.57USD

Change

0.50(+1.00%)

Volume

5,395,656

Today's Range

49.99

 - 

50.85

52 Week Range

42.49

 - 

63.69

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
50.07
Open
50.31
Volume
5,395,656
3M AVG Volume
266.59
Today's High
50.85
Today's Low
49.99
52 Week High
63.69
52 Week Low
42.49
Shares Out (MIL)
1,636.00
Market Cap (MIL)
82,720.71
Forward P/E
11.81
Dividend (Yield %)
3.24

Next Event

Bristol-Myers Squibb Co to Discuss ESMO Highlights Call

Latest Developments

More

Bristol-Myers Squibb Says On September 11, Size Of Board Was Increased To Fourteen

Bristol-Myers Squibb Board Announces Election Of Three New Directors

Bristol‑Myers Squibb Announces Dividend

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bristol-Myers Squibb Co

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.

Industry

Biotechnology & Drugs

Contact Info

430 E 29th St Fl 14

+1.212.5464000

https://www.bms.com/

Executive Leadership

Giovanni Caforio

Chairman of the Board, Chief Executive Officer

Charles A. Bancroft

Chief Financial Officer, Executive Vice President - Global Business Operations

Ann Powell Judge

Chief Human Resource Officer, Senior Vice President

Thomas J. Lynch

Chief Scientific Officer, Executive Vice President

Sandra Leung

Executive Vice President, General Counsel

Key Stats

2.17 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

19.4K

2017

20.8K

2018

22.6K

2019(E)

24.2K
EPS (USD)

2016

2.830

2017

3.010

2018

3.980

2019(E)

4.281
Price To Earnings (TTM)
13.29
Price To Sales (TTM)
3.47
Price To Book (MRQ)
5.16
Price To Cash Flow (TTM)
11.83
Total Debt To Equity (MRQ)
155.64
LT Debt To Equity (MRQ)
152.24
Return on Investment (TTM)
18.38
Return on Equity (TTM)
14.24

Latest News

UPDATE 1-Bristol-Myers' Opdivo fails to meet goal of brain tumor study

Bristol-Myers Squibb Co said on Thursday its blockbuster cancer immunotherapy, Opdivo, failed to meet the main goal of a late-stage trial testing it in patients with a type of tumor that affects the brain and spine.

Amgen to buy Celgene's psoriasis drug Otezla for $13.4 bln in cash

Amgen Inc said on Monday it would buy Celgene Corp's psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene.

Eliquis, Orencia sales propel Bristol-Myers to strong second quarter

Bristol-Myers Squibb Co <BMY.N>, which is set to buy biotechnology company Celgene Corp <CELG.O> for $74 billion, posted better-than-expected second-quarter profit on Thursday on strong sales of blood thinner Eliquis and rheumatoid arthritis treatment Orencia.

Bristol-Myers posts strong second quarter earnings as Eliquis, Orencia surprise

Bristol-Myers Squibb, which is set to buy biotechnology company Celgene Corp soon for $74 billion, posted better-than-expected second-quarter earnings on Thursday on strong sales from its blood thinner Eliquis and rheumatoid arthritis treatment Orencia.

Bristol-Myers releases mixed Opdivo lung cancer results

Bristol-Myers Squibb Co released mixed results on Wednesday from trials testing the survival benefit of its immunotherapy Opdivo in combination with either chemotherapy or its other immuno-oncology drug, Yervoy, as an initial treatment for advanced lung cancer.

Bristol-Myers plans to divest Celgene's psoriasis drug

Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.

Bristol to divest Celgene's psoriasis treatment in FTC clearance push

Bristol-Myers Squibb Co said on Monday it would divest Celgene Corp's psoriasis treatment Otezla as the companies look to gain approval for their $74 billion deal from the U.S. Federal Trade Commission (FTC).

Bristol-Myers' Opdivo fails late-stage brain cancer trial

Bristol-Myers Squibb Co said on Thursday its immunotherapy Opdivo failed to meet the main goal of a late-stage trial testing it in patients with an aggressive form of tumor that affects the brain or the spine.

UPDATE 1-Puerto Rico board files flurry of lawsuits ahead of claim deadline

Puerto Rico's federally created financial oversight board on Tuesday began filing the first round of scores of lawsuits seeking to recover money the bankrupt U.S. commonwealth paid to bondholders, businesses and others.

Bristol-Myers profit slightly tops Wall Street view on blood thinner sales

U.S drugmaker Bristol-Myers Squibb Co, which is set to buy biotechnology company Celgene Corp for $74 billion, posted slightly better-than-expected first-quarter earnings on Thursday on strong sales of its blockbuster blood thinner Eliquis.

Bristol-Myers says shareholders vote to approve Celgene takeover

Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion acquisition of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

Bristol-Myers says shareholders vote to approve Celgene takeover

Bristol-Myers Squibb Inc's shareholders voted to approve the drugmaker's $74 billion takeover of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

Starboard abandons campaign to scuttle Bristol-Myers-Celgene deal

Activist hedge fund Starboard Value LP on Friday abandoned a campaign to convince Bristol-Myers Squibb Co shareholders to vote down the drugmaker's proposed $74 billion takeover of biotech Celgene Corp after the two leading proxy advisory firms backed the deal.

Starboard no longer urging investors to vote against Bristol-Celgene deal

Activist hedge fund Starboard Value LP said on Friday it will no longer urge shareholders to oppose Bristol-Myers Squibb Co's plans to buy Celgene Corp, even though it thinks the deal is too risky and will vote its own shares against it.

UPDATE 1-Starboard no longer urging investors to vote against Bristol-Celgene deal

Activist hedge fund Starboard Value LP said on Friday it will no longer urge shareholders to oppose Bristol-Myers Squibb Co's plans to buy Celgene Corp, even though it thinks the deal is too risky and will vote its own shares against it.

Starboard no longer urging investors to vote against Bristol-Celgene deal

Activist hedge fund Starboard Value LP said on Friday it will no longer urge shareholders to oppose Bristol-Myers Squibb Co's plans to buy Celgene Corp, even though it thinks the deal is too risky and will vote its own shares against it.

REFILE-Proxy advisor ISS backs Bristol takeover of Celgene

Proxy advisory firm Institutional Shareholder Services on Friday recommended shareholders of drugmaker Bristol-Myers Squibb Co shareholders vote in favor of its proposed $74 billion takeover of rival Celgene Corp.

Bristol-Myers, Pfizer defeat Eliquis bleeding risk lawsuits on appeal

A federal appeals court on Tuesday upheld the dismissal of 60 lawsuits alleging Bristol-Myers Squibb and Pfizer Inc concealed information about the dangers of using their blood thinner Eliquis, dealing a major blow to the multidistrict litigation over the drug.

FTC focuses on psoriasis franchise for Bristol-Celgene deal review

The U.S. Federal Trade Commission has sought additional information from Bristol-Myers Squibb Co and Celgene Corp and is focusing on the companies' psoriasis treatments as part of its review of their planned merger, Bristol-Myers said on Tuesday.

FTC seeks more information to review Bristol-Celgene's $74 bln planned merger

The U.S. Federal Trade Commission has sought additional information and documents from Bristol-Myers Squibb Co and Celgene Corp in connection with its review of their planned merger, Bristol-Myers said on Tuesday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up